Depression is a serious condition that occurs more frequently in women and is often associated with treatment resistance. The main hypotheses of this study are that (a) aldosterone is an early marker of depression onset and (b) a tryptophan (TRP) depletion model of depression previously validated in male rats is treatment resistant in females. To explore possible underlying mechanisms, we have focused on factors shown to be altered in patients with treatment-resistant depression. Female Sprague-Dawley rats were treated with a control or low-TRP-containing diet for various time periods up to 21 days. The results show that aldosterone secretion increased after 4 days of TRP depletion and prior to corticosterone. Optimal effects of TRP depletion occurred at 14 days. In addition to neurochemical and behavioural changes observed previously in males, TRP depletion in females was associated with a significant decline in serum magnesium concentrations, increased serum interleukin-6, enhanced gene expression of orexin A in the frontal cortex and induced a rise in N-methyl-D-aspartate (NMDA) receptor Bmax in the amygdala. Depression-like behaviour, NMDA receptor upregulation, enhancement of the kynurenine-to-kynurenic acid ratio and magnesium were resistant to paroxetine treatment (10 mg/kg/day in drinking water for 14 days). In conclusion, aldosterone may represent an important early marker for the onset of depression-like behaviour. With respect to treatment resistance, the underlying mechanisms may involve pro-inflammatory cytokines, the kynurenine pathway, magnesium, glutamate neurotransmission and the orexin pathway. This model of treatment-resistant depression may be useful for the future development of new compounds with novel antidepressant properties.

Keywords:
Tryptophan depletion, Kynurenine pathway, Corticosterone, Paroxetine, Depression-like behaviour
1.
Baune BT, Adrian I, Jacobi F: Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J Psychosom Res 2007;62:109-118.
2.
Hlavacova N, Jezova D: Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 2008;54:90-97.
3.
Jezova D, Hlavacova N: Endocrine factors in stress and psychiatric disorders: focus on anxiety and salivary steroids. Ann NY Acad Sci 2008;1148:495-503.
4.
Hlavacova N, Jezova D: Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul 2008;42:147-153.
5.
Hlavacova N, Bakos J, Jezova D: Eplerenone, a selective mineralocorticoid receptor blocker, exerts anxiolytic effects accompanied by changes in stress hormone release. J Psychopharmacol 2010;24:779-786.
6.
Hlavacova N, Wes PD, Ondrejcakova M, Flynn ME, Poundstone PK, Babic S, Murck H, Jezova D: Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder. Int J Neuropsychopharmacol 2012;15:247-265.
7.
Franklin M, Bermudez I, Hlavacova N, Babic S, Murck H, Schmuckermair C, Singewald N, Gaburro S, Jezova D: Aldosterone increases earlier than corticosterone in new animal models of depression: is this an early marker? J Psychiatr Res 2012;46:1394-1397.
8.
Bay-Richter C, Hallberg L, Ventorp F, Janelidze S, Brundin L: Aldosterone synergizes with peripheral inflammation to induce brain IL-1β expression and depressive-like effects. Cytokine 2012;60:749-754.
9.
Häfner S, Baumert J, Emeny RT, Lacruz ME, Bidlingmaier M, Reincke M, Kuenzel H, Holle R, Rupprecht, R, Ladwig KH; MONICA/KORA Study Investigators: To live alone and to be depressed, an alarming combination for the renin-angiotensin-aldosterone-system (RAAS). Psychoneuroendocrinology 2012;37:230-237.
10.
Häfner S, Baumert J, Emeny RT, Lacruz ME, Bidlingmaier M, Reincke M, Ladwig KH: Hypertension and depressed symptomatology: a cluster related to the activation of the renin-angiotensin-aldosterone system (RAAS). Findings from population based KORA F4 study. Psychoneuroendocrinology 2013;38:2065-2074.
11.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
12.
Grahame-Smith DG: Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem 1971;18:1053-1066.
13.
Franklin M, Cowen PJ, Craven RD: The effect of a low tryptophan diet on brain 5-HT metabolism and 5-HT-mediated neuroendocrine responses in the male rat. J Psychopharmacol 1995;9:336-341.
14.
Franklin M, Craven RD, Cowen PJ: Effect of castration with hormone replacement on the plasma prolactin responses to neuroendocrine challenge with iv mCPP in the male rat following a low tryptophan diet. J Psychopharmacol 1996;10:53-63.
15.
Franklin M, Campling G, Clement EM, Cowen PJ, Craven RD: Effect of long-term TRP depletion on plasma TRP and triglycerides, brain TRP, 5-HT and 5-HIAA. J Psychopharmacol 1996;10:A34.
16.
Franklin M, Craven RD, Dowling B, Campling G, Elliott JM, Cowen PJ: Effect of a long-term low tryptophan diet on the prolactin responses to the 5-HT1A and 5-HT2C agonists, 8-OH-DPAT and mCPP in the male rat. J Psychopharmacol 1999;13:58-63.
17.
Bell C, Abrams J, Nutt D: Tryptophan depletion and its implications for psychiatry. Br J Psychiatry 2001;178:399-405.
18.
Walsh AE, Oldman AD, Franklin M, Fairburn CG, Cowen PJ: Dieting decreases plasma tryptophan and increases the prolactin response to d-fenfluramine in women but not men. J Affect Disord 1995;33:89-97.
19.
Neumeister A, Yuan P, Young TA, Bonne O, Luckenbaugh DA, Charney DS, Manji H: Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry 2005;162:805-807.
20.
Franklin M, Bermudez I, Murck H, Singewald N, Gaburro S: Sub-chronic dietary tryptophan depletion - an animal model of depression with improved face and good construct validity. J Psychiatr Res 2012;46:239-247.
21.
Felger JC, Lotrich FE: Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013;246:199-229.
22.
Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ, Erhardt S, Brundin L: A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression suicidality. Brain Behav Immun 2015;43:110-117.
23.
Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-858.
24.
Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K: Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 2015;77:e19-e20.
25.
Ishitobi Y, Kohno K, Kanehisa M, Inoue A, Imanaga J, Maruyama Y, Ninomiya T, Higuma H, Okamoto S, Tanaka Y, Tsuru J, Hanada H, Isogawa K, Akiyoshi J: Serum ghrelin levels and the effects of antidepressants in major depressive disorder and panic disorder. Neuropsychobiology 2012;66:185-192.
26.
Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR: Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773-3780.
27.
Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, Hayden MR, Wei Y, Ferrario C, Sowers JR: Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008;295:E110-E116.
28.
Porsolt RD, Bertin A, Jalfre M: Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-336.
29.
Franklin M, Odontiadis J: Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat. Pharmacopsychiatry 2003;36:176-180.
30.
Chi JD, Odontiadis J, Franklin M: Simultaneous determination of catecholamines in rat brain tissue by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1999;731:361-367.
31.
Fekkes D, van Dalen A, Edelman M, Voskuilen A: Validation of the determination of amino acids in plasma by high-performance liquid chromatography using automated pre-column derivatization with o-phthaldialdehyde. J Chromatogr B Biomed Appl 1995;669:177-186.
32.
Sumiyoshi T, Ichikawa J, Meltzer HY: The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Neuropsychopharmacology 1997;16:183-190.
33.
Cahir M, Ardis T, Reynolds GP, Cooper SJ: Acute and chronic tryptophan depletion differentially regulate central 5-HT1A and 5-HT2A receptor binding in the rat. Psychopharmacology 2007;190:497-506.
34.
Slater P, McConnell SE, D'Souza SW, Barson AJ: Postnatal changes in N-methyl-D-aspartate receptor binding and stimulation by glutamate and glycine of [3H]-MK-801 binding in human temporal cortex. Br J Pharmacol 1993;108:1143-1149.
35.
Franklin M: Determination of nefazodone and its metabolites in plasma by high-performance liquid chromatography with coulometric detection. J Pharm Biomed Anal 1993;1112:1109-1113.
36.
Neill DW, Neely RA: The estimation of magnesium in serum using titan yellow. J Clin Pathol 1956;9:162-163.
37.
Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH: A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand Suppl 1989;350:60-75.
38.
Varga J, Ferenczi S, Kovács KJ, Garafova A, Jezova D, Zelena D: Comparison of stress-induced changes in adults and pups: is aldosterone the main adrenocortical stress hormone during the perinatal period in rats? PLoS One 2013;8:e72313.
39.
Grinevich V, Seeburg PH, Schwarz MK, Jezova D: Homer 1 - a new player linking the hypothalamic-pituitary-adrenal axis activity to depression and anxiety. Endocr Regul 2012;46:153-159.
40.
Emanuele E, Geroldi D, Minoretti P, Coen E, Politi P: Increased plasma aldosterone in patients with clinical depression. Arch Med Res 2005;6:544-548.
41.
Murck H, Held K, Ziegenbein M, Künzel H, Koch K, Steiger A: The renin-angiotensin-aldosterone system in patients with depression compared to controls - a sleep endocrine study. BMC Psychiatry 2003;3:15.
42.
Singewald N, Sinner C, Hetzenauer A, Sartori SB, Murck H: Magnesium-deficient diet alters depression- and anxiety-related behavior in mice - influence of desipramine and Hypericum perforatum extract. Neuropharmacology 2004;47:1189-1197.
43.
Singewald N, Sartori SB, Gaburro S, Schmuckermair C, Hetzenauer A, Rjabokon A, Franklin M, Bermudez I, Murck H, Shin JH, Lin L, Lubec G, Whittle N: Rodent magnesium-deficiency models for depression and their relationship to NMDA receptor/nitric oxide pathways. Eur Neuropsychopharmacol 2010;20:366.
44.
Murck H: Magnesium and affective disorders. Nutr Neurosci 2002;5:375-389.
45.
Murck H: Ketamine, magnesium and major depression - from pharmacology to pathophysiology and back. J Psychiatr Res 2013;47:955-965.
46.
Wu TC, Chen HT, Chang HY, Yang CY, Hsiao MC, Cheng ML, Chen JC: Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone-induced depression-like behavior. Psychoneuroendocrinology 2013;38:871-883.
47.
Savitz J, Dantzer R, Wurfel BE, Victor TA, Ford BN, Bodurka J, Bellgowan PS, Teague TK, Drevets WC: Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology 2015;52:200-211.
48.
Savitz J, Drevets WC, Wurfel BE, Ford BN, Bellgowan PS, Victor TA, Bodurka J, Teague TK, Dantzer R: Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immunol 2015;46:55-59.
49.
Erhardt S, Olsson SK, Engberg G: Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009;23:91-101.
50.
Myint AM, Kim YK: Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 2014;48:304-313.
51.
Young SN: Mechanism of decline in rat brain 5-hydroxytryptamine after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br J Pharmacol 1981;74:695-700.
52.
Gibney SM, Fagan EM, Waldron AM, O'Byrne J, Connor TJ, Harkin A: Inhibition of stress-induced hepatic tryptophan 2,3-dioxygenase exhibits antidepressant activity in an animal model of depressive behaviour. Int J Neuropsychopharmacol 2014;17:917-928.
53.
Liu W, Sheng H, Xu Y, Liu Y, Lu J, Ni X: Swimming exercise ameliorates depression-like behavior in chronically stressed rats: relevant to proinflammatory cytokines and IDO activation. Behav Brain Res 2013;242:110-116.
54.
Lauterbach EC: An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses 2012;78:693-702.
55.
Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF: Brain biogenetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiarty 2008;63:1127-1134.
56.
Karolewicz B, Szebeni K, Gilmore T, Maciag D, Stockmeier CA, Ordway GA: Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. Int J Neuropsychopharmacol 2009;12:143-153.
57.
Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S, Matsukura S, Kangawa K, Nakazato M: Ghrelin-induced food intake is mediated via the orexin pathway. Endocrinology 2003;144:1506-1512.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.